• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-A12B/A filed by Kezar Life Sciences Inc.

    10/29/24 5:05:27 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email
    8-A12B/A 1 kzr-8-aa_-_rights.htm 8-A12B/A 8-A12B/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ————————————————

    FORM 8-A/A

    ————————————————

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    ————————————————

    Kezar Life Sciences, Inc.

    (Exact name of Registrant as specified in its charter)

     

    ————————————————

    Delaware

    47-3366145

    (State of other jurisdiction of incorporation or organization)

    (I.R.S. Employer I.D. No.)

    4000 Shoreline Court, Suite 300, South San Francisco, CA, 94080
    (Address of principal executive offices)

    Securities to be registered pursuant to Section 12(b) of the Act:

    Title of each class

    to be so registered

    Name of each exchange on which

    each class is to be registered

    Preferred Share Purchase Rights

    The Nasdaq Stock Market LLC

     

    ———————————————————

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

    Securities Act registration statement or Regulation A offering statement file number to which this form relates (if applicable): Not applicable.

    Securities to be registered pursuant to Section 12(g) of the Act:
    None.

     

     


    The undersigned registrant hereby amends the Registration Statement on Form 8-A filed by the registrant with the Securities and Exchange Commission on October 17, 2024 as set forth below:

    Item 1. Description of Securities to be Registered.

    On October 17, 2024, the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”), a Delaware corporation, declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of common stock, par value $0.001 per share, of the Company, and adopted a stockholder rights plan, as set forth in the Rights Agreement, dated as of October 17, 2024 (the “Rights Agreement”), by and between the Company and Computershare Trust Company, N.A., a federally chartered trust company, as rights agent. The dividend was payable to stockholders of record of the Company as of the close of business on October 28, 2024.

    On October 29, 2024, the Company effected a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock by filing with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation (the “Charter Amendment”). Each ten shares of common stock outstanding at the time the Reverse Stock Split was effected were converted into one share of common stock. In connection with the Reverse Stock Split, pursuant to Section 11(o) of the Rights Agreement, the number of shares of Series A Junior Participating Preferred Stock, par value $0.001 per share (the “Preferred Shares”), purchasable upon the exercise of each Right was increased from one one-thousandth of a Preferred Share to one one-hundredth of a Preferred Share and the number of outstanding Rights was decreased by a factor of ten such that each share of common stock outstanding immediately after the Reverse Stock Split has issued with respect to it one Right. The exercise price of each Right was also adjusted such that each Right will allow its holder to purchase from the Company one one-hundredth of a Preferred Share for $71.60, once the Rights become exercisable.

    The Rights are in all respects subject to and governed by the provisions of the Rights Agreement, which is attached to this Registration Statement on Form 8-A/A as Exhibit 4.1 and is incorporated herein by reference. The description of the Rights is incorporated herein by reference to the description set forth under Items 1.01, 3.03 and 5.03 of the Company’s Current Report on Form 8-K filed on October 17, 2024 and is qualified in its entirety by reference to the full text of the Rights Agreement. The description of the Reverse Stock Split is incorporated by reference to the description set forth under Item 3.03 of the Company’s Current Report on Form 8-K filed on October 28, 2024 and is qualified in its entirety by reference to the full text of the Charter Amendment, which is attached to this Registration Statement on Form 8-A/A as Exhibit 3.2 and is incorporated herein by reference.

    Item 2. Exhibits.

     

     

     

    Exhibit

    No.

     

    Description

     

     

    3.1

     

    Certificate of Designations of Series A Junior Participating Preferred Stock of Kezar Life Sciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on October 17, 2024).

     

     

    3.2

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on October 28, 2024).

     

     

     

    4.1

     

    Rights Agreement, dated as of October 17, by and between Kezar Life Sciences, Inc. and Computershare Trust Company, N.A., as rights agent, which includes the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on October 17, 2024).

     


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

    Dated: October 29, 2024

     

     

     

    KEZAR LIFE SCIENCES, INC.

     

     

    By:

     

    /s/ Marc L. Belsky

     

     

    Name: Marc L. Belsky

     

     

    Title: Chief Financial Officer and Secretary

     


    Get the next $KZR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    10/17/2025$7.00Buy → Hold
    Jefferies
    10/17/2025Outperform → Mkt Perform
    William Blair
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Schiller Mark C. sold $2,401 worth of shares (561 units at $4.28), decreasing direct ownership by 17% to 2,739 units (SEC Form 4)

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/3/25 4:15:27 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Corporate Controller Chiang Pichi Luo sold $1,130 worth of shares (264 units at $4.28), decreasing direct ownership by 9% to 2,711 units (SEC Form 4)

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/3/25 4:15:28 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Development Officer To Zung Phuong

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/1/25 5:25:28 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    SEC Filings

    View All

    SEC Form 10-Q filed by Kezar Life Sciences Inc.

    10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/12/25 4:21:30 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/12/25 4:07:21 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/7/25 4:21:15 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory AIH. As part of the briefing package submitted to the FDA, Kezar submitt

    1/9/26 6:01:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Reports Third Quarter 2025 Financial Results

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder value. Kezar has retained TD Cowen to support it with the

    11/12/25 4:01:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2a PORTOLA clinical trial in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025 held by the American Association for the Study of Liver Disease (AASLD) and taking place November 7-11, in Washington, DC. The presentation details are as follows: Oral Presentation Title: Zetomipzomib, a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrates Steroid Sparing Biochemical Remission in Patients with Relapsed or Insufficiently Responding Auto

    11/7/25 7:01:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by William Blair

    William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

    10/17/25 8:25:32 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

    8/11/23 7:45:02 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Financials

    Live finance-specific insights

    View All

    Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

    Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

    3/25/25 7:30:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

    10/17/24 8:35:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

    3/13/23 7:00:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Leadership Updates

    Live Leadership Updates

    View All

    Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

    Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer   Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment

    10/3/23 4:10:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

    Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone

    8/11/22 4:01:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted

    8/3/22 4:30:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Kezar Life Sciences Inc.

    SC 13D - Kezar Life Sciences, Inc. (0001645666) (Subject)

    10/8/24 4:20:17 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kezar Life Sciences Inc.

    SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

    7/8/24 4:32:39 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

    SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

    2/14/24 6:47:29 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care